Last reviewed · How we verify
Auryxia (FERRIC CITRATE)
Auryxia works by binding to phosphate in the gut, reducing its absorption, and also providing iron to the body.
Auryxia (FERRIC CITRATE) is a small molecule drug developed by Keryx Biopharms, currently owned by the same company. It is used to treat hyperphosphatemia and iron deficiency anemia. Auryxia is a ferric citrate, a type of iron replacement therapy. It is FDA-approved and has a commercial status of patented, with a generic manufacturer available. Key safety considerations include monitoring of serum phosphorus levels and potential gastrointestinal side effects.
At a glance
| Generic name | FERRIC CITRATE |
|---|---|
| Sponsor | Keryx Biopharms |
| Drug class | ferric citrate |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 2014 |
Mechanism of action
Imagine your body as a bucket with two separate compartments: one for phosphate and one for iron. Auryxia helps by filling the iron compartment, while also using a special 'mop' to clean up excess phosphate in the gut, preventing it from entering the body.
Approved indications
- Hyperphosphatemia
- Iron deficiency anemia
Common side effects
- Discolored feces
- Diarrhea
- Constipation
- Nausea
- Vomiting
- Cough
- Abdominal pain
- Hyperkalemia
Drug interactions
- dolutegravir
- enoxacin
- levodopa
- levofloxacin
- levothyroxine sodium
- lomefloxacin
- minocycline
- moxifloxacin
- mycophenolate mofetil
- norfloxacin
- ofloxacin
Key clinical trials
- Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease (PHASE3)
- Ferric Citrate in Iron Deficiency Anemia During Pregnancy (PHASE3)
- Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease (PHASE3)
- Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease (PHASE3)
- The Efficacy of Minayo Iron-rich Nutritional Gummies on Female Anemia, Skin Condition and Qi-blood Deficiency Syndrome (NA)
- PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD (PHASE3)
- Ferric Citrate and Chronic Kidney Disease in Children (PHASE2)
- Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Auryxia CI brief — competitive landscape report
- Auryxia updates RSS · CI watch RSS
- Keryx Biopharms portfolio CI